AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan). This review is for the treatment of adult patients…
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). This designation is granted…
AIVITA Biomedical, Inc., a biotech firm focused on pioneering stem cell applications, has announced a licensing agreement with LevEllis, a global skincare retailer. This partnership grants LevEllis the exclusive worldwide marketing and distribution rights to AIVITA’s proprietary skincare formulations, previously…
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics and technology company, and Biotheus Inc., a clinical-stage biotech specializing in biologics for oncology and inflammatory diseases, have announced the signing of a Material Transfer and Evaluation Agreement (MTEA). This agreement…
Arcus Biosciences, Inc. (NYSE: RCUS), a global biopharmaceutical company in the clinical stage, focused on developing innovative molecules and combination therapies for cancer patients, has announced a new collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership aims to evaluate the combination…
ImmunoTek Bio Centers, the largest independent operator and developer of blood plasma donation centers in the United States, is thrilled to announce its participation in International Plasma Awareness Week (IPAW) from October 7-11, 2024. During this special week, the community…
PBIRx, Inc., a leader in pharmacy benefit consulting and auditing, is proud to announce the promotion of Stacy Mathews, MBA, to Director of Account Management. Since joining PBIRx as a Senior Account Consultant, Stacy has made a remarkable impact, leveraging…
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, recently announced promising data from a study evaluating camonsertib, an oral small molecule ATR inhibitor, in combination with palliative radiation for treating metastatic tumors with an ataxia-telangiectasia-mutated (ATM) mutation. The…
Lupin Limited, a leading global pharmaceutical company, has announced that its subsidiary, Lupin Atlantis Holdings SA, has entered into a distribution agreement with Celnova Pharma for the commercialization of its orphan drug, NaMuscla® (mexiletine). Celnova will be responsible for distributing…
Artera, a pioneer in multimodal artificial intelligence (MMAI) for prognostic and predictive cancer testing, is set to present two oral abstracts at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. The company’s MMAI platform utilizes advanced AI algorithms…
eClinical Solutions LLC, a global leader in digital clinical software and services, is set to host its sixth annual client and partner conference, ENGAGE 2024, on Thursday, October 10 and Friday, October 11. This event will bring together top technology…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the positive benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for first-line…
